Date Filed | Type | Description |
10/03/2023 |
4
| Edwards Larry Todd (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 60,000 shares
@ $0 Granted 240,000 options to buy
@ $5.58, valued at
$1.3M
|
|
10/03/2023 |
3
| Edwards Larry Todd (Chief Commercial Officer) has filed a Form 3 on Arcutis Biotherapeutics, Inc. |
09/27/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/22/2023 |
4
| Burnett Patrick (See Remarks) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 300 shares
@ $7.05, valued at
$2.1k
Sold 1,305 shares
@ $7.04, valued at
$9.2k
|
|
08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/18/2023 |
8-K
| Quarterly results |
08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
08/14/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/08/2023 |
8-K
| Quarterly results |
06/02/2023 |
4
| Matsuda Masaru (See Remark) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,875 shares
@ $0 Sold 1,830 shares
@ $7.8023, valued at
$14.3k
Granted 1,463 shares
@ $6.38, valued at
$9.3k
|
|
06/02/2023 |
4
| LIN SUE-JEAN (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Heron Patrick J (10% Owner) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| CHAUDHURI BHASKAR (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Curran Terrie (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Gilbert Halley E (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Leonard Keith R (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Krishnamohan Neha (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
06/02/2023 |
4
| Welgus Howard G. (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 4,375 shares
@ $0 Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/24/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/09/2023 |
8-K
| Quarterly results |
04/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/18/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
03/31/2023 |
4/A
| Watanabe Todd Franklin (See Remarks) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Granted 87,500 shares
@ $0 Granted 232,000 options to buy
@ $15.82, valued at
$3.7M
|
|
03/08/2023 |
4
| Watanabe Todd Franklin (See Remarks) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 2,435 shares
@ $15.2638, valued at
$37.2k
|
|
03/08/2023 |
4
| Burrows Scott L (CFO) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 291 shares
@ $15.2634, valued at
$4.4k
|
|
03/08/2023 |
4
| Burnett Patrick (See Remarks) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 851 shares
@ $15.2634, valued at
$13k
|
|
03/08/2023 |
4
| Turney Patricia A. (SVP, Operations) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 831 shares
@ $15.2635, valued at
$12.7k
|
|
03/08/2023 |
4
| OSBORNE DAVID W (Chief Technical Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 690 shares
@ $15.2634, valued at
$10.5k
|
|
03/08/2023 |
4
| Lock Kenneth A. (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
Txns:
| Sold 831 shares
@ $15.2636, valued at
$12.7k
|
|
|